Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations

Amivantamab is a bispecific antibody that recognizes epidermal growth factor receptor (EGFR) and MET proto-oncogene (MET). In May 2021, the Food and Drug Administration gave an accelerated approval of amivantamab for the treatment of non-small cell lung cancer (NSCLC) patients with EGFR exon 20 inse...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrini, Iacopo, Giaccone, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555392/
https://www.ncbi.nlm.nih.gov/pubmed/36246734
http://dx.doi.org/10.2147/OTT.S329095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555392/
https://www.ncbi.nlm.nih.gov/pubmed/36246734
http://dx.doi.org/10.2147/OTT.S329095

Ejemplares similares